Ultragenyx Pharmaceutical
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Ultragenyx Pharmaceutical generated cash of -$474,806,000, which is less than the previous year. Cash used in financing activities reached the amount of $388,142,000 last year. Net change in cash is therefore $81,798,000.
Cash Flow
| 2014 | -44.63M | -123.44M | 184.97M |
|---|---|---|---|
| 2015 | -105.97M | -292.35M | 467.57M |
| 2016 | -160.97M | 89.91M | 138.67M |
| 2017 | -253.84M | 56.41M | 136.26M |
| 2018 | -290.56M | -33.33M | 336.85M |
| 2019 | -345.38M | -13.03M | 679.30M |
| 2020 | -132.22M | -179.12M | 600.27M |
| 2021 | -338.69M | -195.37M | 118.55M |
| 2022 | -380.46M | -291.65M | 501.20M |
| 2023 | -474.80M | 168M | 388.14M |
RARE Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 137.60M | 309.58M | 726.29M | 436.24M | 115.52M | 103.04M | 161.12M | 93.56M | 24.32M | 7.42M |
Operating activities | ||||||||||
Net income | -606.63M | -707.42M | -454.02M | -186.56M | -402.72M | -197.61M | -302.13M | -245.87M | -145.61M | -59.80M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 26.00M | 18.22M | 13.23M | 12.26M | 8.53M | 19.53M | 5.82M | 3.42M | 1.38M | 684K |
Stock-based compensation expense | 135.21M | 130.37M | 104.95M | 85.73M | 81.99M | 0 | 68.01M | 48.30M | 24.88M | 5.39M |
| Deferred income tax benefit | 135.21M | 130.37M | 104.95M | 85.73M | 81.99M | 0 | 68.01M | 48.30M | 24.88M | 5.39M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -22.77M | -12.06M | -5.43M | 9.84M | -20.10M | -7.58M | -5.17M | 0 | 0 | 0 |
Inventories | -6.93M | -9.70M | -3.11M | -1.34M | -4.45M | -5.28M | -757K | 0 | 0 | 0 |
Accounts payable | 2.38M | 87.44M | 2.80M | 29.60M | 20.64M | 3.37M | 3.45M | 2.50M | -1.98M | 3.17M |
Cash generated by operating activities | -474.80M | -380.46M | -338.69M | -132.22M | -345.38M | -290.56M | -253.84M | -160.97M | -105.97M | -44.63M |
Investing activities | ||||||||||
Purchases Of Investments | -526.38M | -614.73M | -1.01B | -850.29M | -707.16M | -509.79M | -230.48M | -442.49M | -624.22M | -208.97M |
Investments In Property Plant And Equipment | -44.26M | -146.12M | -73.09M | -43.90M | -24.83M | -4.07M | -2.79M | -10.18M | -4.95M | -2.14M |
Acquisitions Net | 0 | -75.02M | 0 | 0 | -11.79M | 0 | -142.80M | 0 | 0 | 0 |
Cash generated by investing activities | 168M | -291.65M | -195.37M | -179.12M | -13.03M | -33.33M | 56.41M | 89.91M | -292.35M | -123.44M |
Financing activities | ||||||||||
Common Stock Issued | 379.75M | 10.81M | 78.94M | 511.21M | 355.24M | 0 | 131.96M | 79.48M | 467.57M | 189.31M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.34M |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | -4.94M | 0 | 0 | 0 |
Cash used in financing activities | 388.14M | 501.20M | 118.55M | 600.27M | 679.30M | 336.85M | 136.26M | 138.67M | 467.57M | 184.97M |
Net Change In Cash | 81.79M | -171.98M | -416.70M | 290.05M | 320.71M | 12.48M | -60.63M | 67.55M | 69.24M | 16.89M |
Cash at end of period | 219.39M | 137.60M | 309.58M | 726.29M | 436.24M | 115.52M | 100.48M | 161.12M | 93.56M | 24.32M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |